Ocugen announced it will advance its gene therapy for geographic atrophy, a form of vision loss, to a Phase 3 clinical trial. The decision comes after the company reported mixed results from a smaller Phase 2 study on Tuesday.
Geographic atrophy is an advanced form of dry age-related macular degeneration that leads to progressive vision loss. Current treatment options for this condition are limited, making new therapeutic approaches particularly significant for patients and the ophthalmology field.